Cargando…

An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes

Stiff person syndrome (SPS) is a rare central nervous system disorder associated with malignancies. In this review, we retrieved information from PubMed, up until August 2023, using various search terms and their combinations, including SPS, stiff person syndrome spectrum disorders (SPSSDs), paraneo...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Yong, Yang, Huan, Xue, Ya-hui, Chen, Quan, Jin, Hong, Liu, Shu, Yao, Shun-yu, Du, Miao-qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582361/
https://www.ncbi.nlm.nih.gov/pubmed/37859648
http://dx.doi.org/10.3389/fneur.2023.1209302
_version_ 1785122313001238528
author Peng, Yong
Yang, Huan
Xue, Ya-hui
Chen, Quan
Jin, Hong
Liu, Shu
Yao, Shun-yu
Du, Miao-qiao
author_facet Peng, Yong
Yang, Huan
Xue, Ya-hui
Chen, Quan
Jin, Hong
Liu, Shu
Yao, Shun-yu
Du, Miao-qiao
author_sort Peng, Yong
collection PubMed
description Stiff person syndrome (SPS) is a rare central nervous system disorder associated with malignancies. In this review, we retrieved information from PubMed, up until August 2023, using various search terms and their combinations, including SPS, stiff person syndrome spectrum disorders (SPSSDs), paraneoplastic, cancer, and malignant tumor. Data from peer-reviewed journals printed in English were organized to explain the possible relationships between different carcinomas and SPSSD subtypes, as well as related autoantigens. From literature searching, it was revealed that breast cancer was the most prevalent carcinoma linked to SPSSDs, followed by lung cancer and lymphoma. Furthermore, classic SPS was the most common SPSSD subtype, followed by stiff limb syndrome and progressive encephalomyelitis with rigidity and myoclonus. GAD65 was the most common autoantigen in patients with cancer and SPSSDs, followed by amphiphysin and GlyR. Patients with cancer subtypes might have multiple SPSSD subtypes, and conversely, patients with SPSSD subtypes might have multiple carcinoma subtypes. The first aim of this review was to highlight the complex nature of the relationships among cancers, autoantigens, and SPSSDs as new information in this field continues to be generated globally. The adoption of an open-minded approach to updating information on new cancer subtypes, autoantigens, and SPSSDs is recommended to renew our database. The second aim of this review was to discuss SPS animal models, which will help us to understand the mechanisms underlying the pathogenesis of SPS. In future, elucidating the relationship among cancers, autoantigens, and SPSSDs is critical for the early prediction of cancer and discovery of new therapeutic modalities.
format Online
Article
Text
id pubmed-10582361
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105823612023-10-19 An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes Peng, Yong Yang, Huan Xue, Ya-hui Chen, Quan Jin, Hong Liu, Shu Yao, Shun-yu Du, Miao-qiao Front Neurol Neurology Stiff person syndrome (SPS) is a rare central nervous system disorder associated with malignancies. In this review, we retrieved information from PubMed, up until August 2023, using various search terms and their combinations, including SPS, stiff person syndrome spectrum disorders (SPSSDs), paraneoplastic, cancer, and malignant tumor. Data from peer-reviewed journals printed in English were organized to explain the possible relationships between different carcinomas and SPSSD subtypes, as well as related autoantigens. From literature searching, it was revealed that breast cancer was the most prevalent carcinoma linked to SPSSDs, followed by lung cancer and lymphoma. Furthermore, classic SPS was the most common SPSSD subtype, followed by stiff limb syndrome and progressive encephalomyelitis with rigidity and myoclonus. GAD65 was the most common autoantigen in patients with cancer and SPSSDs, followed by amphiphysin and GlyR. Patients with cancer subtypes might have multiple SPSSD subtypes, and conversely, patients with SPSSD subtypes might have multiple carcinoma subtypes. The first aim of this review was to highlight the complex nature of the relationships among cancers, autoantigens, and SPSSDs as new information in this field continues to be generated globally. The adoption of an open-minded approach to updating information on new cancer subtypes, autoantigens, and SPSSDs is recommended to renew our database. The second aim of this review was to discuss SPS animal models, which will help us to understand the mechanisms underlying the pathogenesis of SPS. In future, elucidating the relationship among cancers, autoantigens, and SPSSDs is critical for the early prediction of cancer and discovery of new therapeutic modalities. Frontiers Media S.A. 2023-10-04 /pmc/articles/PMC10582361/ /pubmed/37859648 http://dx.doi.org/10.3389/fneur.2023.1209302 Text en Copyright © 2023 Peng, Yang, Xue, Chen, Jin, Liu, Yao and Du. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Peng, Yong
Yang, Huan
Xue, Ya-hui
Chen, Quan
Jin, Hong
Liu, Shu
Yao, Shun-yu
Du, Miao-qiao
An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes
title An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes
title_full An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes
title_fullStr An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes
title_full_unstemmed An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes
title_short An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes
title_sort update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582361/
https://www.ncbi.nlm.nih.gov/pubmed/37859648
http://dx.doi.org/10.3389/fneur.2023.1209302
work_keys_str_mv AT pengyong anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT yanghuan anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT xueyahui anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT chenquan anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT jinhong anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT liushu anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT yaoshunyu anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT dumiaoqiao anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT pengyong updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT yanghuan updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT xueyahui updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT chenquan updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT jinhong updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT liushu updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT yaoshunyu updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes
AT dumiaoqiao updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes